Governance Neutral

2026-10-13 17:24

- Asston Pharmaceuticals Ltd announced a change in its registered office address within the same city and ROC jurisdiction. - The new registered office will be at Office No. 1437 and 1438, 24 High, Service Road, MIDC Industrial Area, Shiravane, Nerul, Navi Mumbai - 410210. - The change is effective from 15th October 2026.

Routine Neutral

2026-10-13 17:18

- The Board of Directors approved shifting the company's registered office within the same city and ROC jurisdiction. - New Address: Office No. 1437 and 1438, 24 High, Service Road, MIDC Industrial Area, Shiravane, Nerul, Navi Mumbai, Maharashtra – 410210. - Effective Date: 15th October 2026.

Governance Neutral

2026-10-06 18:27

- Asston Pharmaceuticals Ltd has intimated that a Board Meeting is scheduled to be held on Tuesday, 13th October, 2026. - Purpose of the meeting is to consider and approve the shifting of the registered office address of the Company. - The board will also consider and approve the acquisition of immovable property through Bank/Financial Institution Auction.

Governance Neutral

2026-10-01 14:04

- Asston Pharmaceuticals Limited announced the outcome of its 7th Annual General Meeting held on September 29, 2026. - Approved adoption of Audited Standalone financial statements for FY ended March 31, 2026. - Approved re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director retiring by rotation. - Approved appointment of M/s Panchal S K & Associates as Statutory Auditors. - Approved increase in remuneration for key managerial personnel including the MD, Whole-time Director/CEO, and Non-Executive Director.

Governance Neutral

2026-10-01 14:04

- AGM held on September 29, 2026, approved financial statements for FY ended March 31, 2026. - Re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director liable to retire by rotation. - Appointment of M/s Panchal S K & Associates as Statutory Auditors. - Approved increase in remuneration for key managerial personnel.

Governance Neutral

2026-10-01 13:02

- Asston Pharmaceuticals Limited held its 7th Annual General Meeting (AGM) on September 29, 2026, through Video Conferencing. - Pragya Jain of M/s Pragya & Associates acted as the scrutinizer for the e-voting process. - A total of 6 resolutions were considered and passed with requisite majority by the shareholders. - Key resolutions included the adoption of audited financial statements for FY 2025-26 and the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director.

Governance Neutral

2026-09-29 13:14

- Asston Pharmaceuticals Limited held its 7th Annual General Meeting (AGM) on September 29, 2026, via video conferencing. - Shareholders considered and voted on the adoption of audited financial statements for FY 2025-26, retirement by rotation of Managing Director Mr. Ashish Narayan Sakalkar, and appointment of statutory auditors M/s Panchal S K & Associates. - Special business items included approval of increased remuneration for key managerial personnel and directors including Mr. Ashish Narayan Sakalkar, Mrs. Saili Jayaram More, and Mr. Sachin Chandrakant Badakh.

Routine Neutral

2026-09-27 14:42

- Trading window closed effective from October 1, 2026. - Closure remains in effect until 48 hours after the declaration of Unaudited Financial Results for the half year ended September 30, 2026. - Board meeting date to approve results will be intimated in due course.

Ownership Positive

2026-09-05 13:14

- Asston Pharmaceuticals Limited approved the preferential allotment of 2,410,431 equity shares at ₹115/- per share (including a premium of ₹105/-) to 15 investors. - This allotment increases the paid-up equity share capital to ₹109,227,910.

Ownership Positive

2026-09-05 13:10

- Board approved the allotment of 24,10,431 equity shares of face value ₹10/- each, at an issue price of ₹115/- per share (including premium of ₹105/-). This increases the paid-up equity share capital to ₹10,92,27,910/- comprising 1,09,22,791 shares. The preferential allotment was made to 15 investors.

Governance Neutral

2026-09-04 19:48

- Board of Directors meeting held on September 4, 2026. - Approved the appointment of M/s Yash A. Jain & Associates as Internal Auditor and M/s Panchal S K & Associates as Statutory Auditors. - Approved the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director. - Proposed increases in remuneration for Mr. Ashish Narayan Sakalkar (MD), Mrs. Saili Jayaram More (WTD & CEO), and Mr. Sachin Chandrakant Badakh (Non-Executive Director), subject to members' approval. - Approved the Board's Report for the financial year ended March 31, 2026. - The 7th Annual General Meeting (AGM) is scheduled for September 29, 2026, at 12:30 P.M. via Video Conferencing. - The cut-off date for e-voting for the AGM is September 22, 2026.

Governance Neutral

2026-09-04 19:39

- Board met on Sep 04, 2026, approving internal and statutory auditor appointments. - Re-appointed Mr. Ashish Narayan Sakalkar as MD, proposing remuneration increases for MD, WTD & CEO, and Non-Executive Director. - 7th AGM on Sep 29, 2026; e-voting cut-off is Sep 22, 2026.

Governance Neutral

2026-09-04 19:39

- Board meeting held on September 04, 2026. - Approved the appointment of M/s Yash A. Jain & Associates as Internal Auditor. - Approved the appointment of M/s Panchal S K & Associates as Statutory Auditors. - Recommended re-appointment and proposed remuneration increase for Mr. Ashish Narayan Sakalkar (MD). - Proposed remuneration increases for Mrs. Saili Jayaram More (Whole-time Director & CEO) and Mr. Sachin Chandrakant Badakh (Non-Executive Director). - Approved the Board's Report and MD&A for the financial year ended March 31, 2026. - Approved the convening of the 7th Annual General Meeting on September 29, 2026, via Video Conferencing/OAVM.

Governance Neutral

2026-09-04 19:38

- Board of Directors met on September 04, 2026. - Approved appointment of new Internal & Statutory Auditors. - Approved re-appointment of MD Mr. Ashish Narayan Sakalkar and proposed remuneration increases for MD, Whole-time Director & CEO, and Non-Executive Director (all subject to member approval). - The 7th Annual General Meeting (AGM) is scheduled for September 29, 2026, at 12:30 P.M. via Video Conferencing.

Governance Neutral

2026-09-04 19:33

- The Board approved the appointment of M/s Yash A. Jain & Associates as Internal Auditor and M/s Panchal S K & Associates as Statutory Auditors. - Re-appointment of Mr. Ashish Narayan Sakalkar (MD), Mrs. Saili Jayaram More (WTD & CEO), and Mr. Sachin Chandrakant Badakh (Non-Executive Director) with proposed remuneration increases, subject to members' approval. - The 7th Annual General Meeting (AGM) is scheduled for September 29, 2026, and September 22, 2026, is the e-voting cut-off date.

Ownership Neutral

2026-09-04 11:16

- Prakruti R Pali acquired 1,51,000 equity shares of Asston Pharmaceuticals Limited through an open market purchase on September 01, 2026. - This acquisition represents 1.77% of the total share/voting capital. - Post-acquisition, the acquirer's holding increased from 7.26% (6,18,000 shares) to 9.03% (7,69,000 shares).

Ownership Positive

2026-09-02 11:38

- Prakruti R Pali acquired 1,64,000 equity shares (1.93%) of Asston Pharmaceuticals Limited via open market on August 28, 2026. - Post-acquisition, the acquirer's holding increased from 5.33% to 7.26%.

Ownership Positive

2026-09-01 10:44

- Mrs. Prakruti R Pali acquired 2,40,000 equity shares of Asston Pharmaceuticals Limited via open market on August 27, 2026. - This increased her stake from 2.51% (2,14,000 shares) to 5.33% (4,54,000 shares).

Ownership Neutral

2026-08-31 16:12

- Acquirer Prakruti R Pali acquired 2,40,000 equity shares of Asston Pharmaceuticals Limited via open market on August 27, 2026. - Holding increased from 2.51% (2,14,000 shares) to 5.33% (4,54,000 shares) post-acquisition.

Governance Positive

2026-08-03 19:45

- Extraordinary General Meeting (EGM) of Asston Pharmaceuticals Limited was held on July 31, 2026. - A special resolution to issue equity shares on a preferential basis was passed with 100% votes in favour. - Total 4,682,584 votes were cast in favour of the resolution.

Governance Neutral

2026-07-31 13:17

- Outcome and proceedings of the 2nd Extraordinary General Meeting (EGM) for FY 2026-27 held on Friday, July 31, 2026, at 12:30 P.M. via Video Conferencing. - The EGM discussed resolutions, including one to issue equity shares on a preferential basis. - Voting results are to be declared within 2 working days from the conclusion of the EGM.

Governance Neutral

2026-07-09 16:50

- Asston Pharmaceuticals Limited to hold its 2nd Extraordinary General Meeting (EGM) on Friday, July 31, 2026, at 12:30 P.M. via Video Conferencing/Other Audio Visual Means. - The EGM's agenda is to approve the issuance of up to 24,10,431 equity shares on a preferential basis at an issue price of ₹115 per share, aggregating up to ₹27,71,99,565/-. - The cut-off date for determining e-voting eligibility is July 24, 2026.

Governance Positive

2026-07-02 18:49

- Board of Directors approved the preferential issue of up to 24,10,431 Equity Shares at ₹115 per share, aggregating ₹27.72 Crores, to Non-Promoter category. - An EGM will be convened on July 31, 2026, at 12:30 PM to obtain shareholder approval for the preferential issue.

Ownership Positive

2026-07-02 18:43

- Board of Directors approved the preferential issue of up to 24,10,431 equity shares to persons belonging to the Non-Promoter category. - The issue price is ₹115 per equity share, aggregating up to ₹27,71,99,565. - An Extraordinary General Meeting (EGM) will be held on Friday, July 31, 2026, at 12:30 PM to seek shareholder approval for the proposed issue.

Governance Positive

2026-07-02 18:37

- Board approved preferential issue of up to 24,10,431 equity shares at ₹115 per share, totaling ₹27.72 Crore, to non-promoters on a cash basis. - An EGM is scheduled for July 31, 2026, at 12:30 PM to obtain shareholder approval for this preferential issue.

Ownership Positive

2026-07-02 18:27

- Board approved preferential issue of up to 24,10,431 Equity Shares at ₹115 per share (totaling ₹27.72 Crores) to non-promoters for cash. - An EGM is scheduled for July 31, 2026, at 12:30 PM to seek shareholder approval for the proposed issue.

Governance Positive

2026-07-02 18:24

- Board of Directors approved the preferential issue of up to 24,10,431 Equity Shares at ₹115 per share, aggregating ₹27.72 Crores to Non-Promoters. - An Extraordinary General Meeting (EGM) is scheduled for Friday, July 31, 2026, at 12:30 PM to seek shareholder approval for the preferential issue.

Governance Neutral

2026-06-24 18:56

- Board Meeting to be held on July 02, 2026, to consider a proposal for raising funds, including a preferential issue. - Trading window for dealing in company securities will be closed from June 24, 2026, to July 04, 2026.

Governance Positive

2026-06-24 18:41

- Board meeting scheduled for Thursday, July 02, 2026, to consider a proposal for raising funds, including a preferential issue. - Trading window for dealing in company securities will be closed from June 24, 2026, to July 04, 2026.

Financials Negative

2026-05-29 22:06

Standalone Revenue from Operations for the year ended 31st March 2026 was ₹25.47 Cr vs ₹25.04 Cr (▲1.72% YoY). EBITDA was -₹0.57 Cr vs ₹5.44 Cr (▼110.40% YoY). PAT was ₹3.87 Cr vs ₹3.85 Cr (▲0.32% YoY). EBITDA Margin was -2.22% vs 21.71% (▼2393bps). The company reported audited financial results for the year and half year ended 31st March 2026, with auditors issuing an unmodified opinion.

Financials Negative

2026-05-29 22:03

Standalone Annual Revenue for the year ended March 31, 2026, was ₹2,546.88 Lakhs compared to ₹2,503.92 Lakhs in the previous year (▲1.72% YoY). EBITDA was -₹66.95 Lakhs against ₹543.58 Lakhs (▼112.31% YoY). Net Profit (PAT) was ₹386.52 Lakhs compared to ₹385.28 Lakhs (▲0.32% YoY). EBITDA Margin contracted significantly from 21.71% to -2.63% (▼2434 bps).

Financials Negative

2026-05-29 21:51

Revenue ₹2,546.88 Lakhs vs ₹2,503.92 Lakhs (▲1.72% YoY), EBITDA ₹555.02 Lakhs vs ₹600.68 Lakhs (▼7.60% YoY), PAT ₹386.52 Lakhs vs ₹385.28 Lakhs (▲0.32% YoY). EBITDA Margin 21.79% vs 23.99% (▼220bps).

Governance Neutral

2026-05-21 20:52

ASSTON PHARMACEUTICALS LIMITED announced that a Board Meeting will be held on Friday, 29th May, 2026, at 3:00 P.M. to consider and approve the Audited Financial Statements and Financial Results for the Financial Year and Quarter ended March 31, 2026. The board will also consider the statement of deviation of funds as per SEBI regulations.

544445

Asston Pharmaceuticals Ltd

Price Chart

Filing History

Unlock Full History